Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its ...

Planegg/Martinsried, November 26, 2024.Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research ...

Planegg/Martinsried, November 11, 2024.Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused ...

has selected a third target as part of its immuno-oncology partnership with GlaxoSmithKline. The collaboration was first launched in 2013, and is based around Immunocore’s T Cell Receptor (TCR ...

Immuno-oncology (IO) has transformed cancer care ... led to the discovery of novel multi-specific antibodies that target TCR variable beta (Vβ)-chain variants—powerfully activating the right ...

Which is best suited for immuno-oncology? Cancer research and drug ... Checkpoint inhibitors, CAR-T cells, modified TCR T cells, and vaccines in various forms are now the frontier of oncology ...